Coating stents with antirestenotic drugs: the blunderbuss or the magic bullet?
Lowe
Harry C
HC
Khachigian
Levon M
LM
D000800:Angioplasty, Balloon / Q000009:adverse effects; D000818:Animals; D021881:DNA, Catalytic / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods; D051766:Early Growth Response Protein 1; D018390:Gene Targeting; D006083:Graft Occlusion, Vascular / Q000188:drug therapy* / Q000628:therapy*; D006801:Humans; D017874:Immediate-Early Proteins; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D020123:Sirolimus / Q000494:pharmacology / Q000627:therapeutic use*; D015607:Stents / Q000009:adverse effects; D013552:Swine; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism
D021881:DNA, Catalytic; D004268:DNA-Binding Proteins; C497325:EGR1 protein, human; D051766:Early Growth Response Protein 1; C486110:Egr1 protein, rat; D017874:Immediate-Early Proteins; D012333:RNA, Messenger; D014157:Transcription Factors; D020123:Sirolimus